Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability and clinical activity of ASM-024 in stable moderate asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asmacure Ltée

Criteria

Inclusion Criteria:

• Able and willing to provide written informed consent.

• Male or female subjects, ≥ 18 years and ≤ 55 years of age

• Diagnosis of moderate asthma and on regular inhaled corticosteroids with or without short or long-acting Beta-2-agonists

• FEV1 ≥ 55 % predicted in the absence of medications for asthma

• Female subjects of childbearing potential must have a negative pregnancy test (serum beta-human chorionic gonadotropin (b-HCG)) at Screening, and a negative pregnancy test immediately before the administration of the study drug for each of Periods 1, 2 and

3. Sexually active females with non-sterile partner must be willing to use adequate contraception.

• Male subjects must be willing to use a condom with a spermicide for the duration of their participation in the study, plus an additional 30 days following study drug administration and ensure that their partner is using a highly effective method of birth control such as combined oral contraceptives, implants, injectables or an intra-uterine device (IUD). Male subjects must ensure that their female partner is willing to use adequate contraception.

• Demonstration of an increase in FEV1 by ≥ 10 % predicted between spirometry performed before and 10-20 minutes after the administration of 2 puffs of 100 micrograms of salbutamol at Screening.

Exclusion Criteria:

• Clinically significant conditions or illnesses other than moderate asthma or systemic diseases

• Pregnant or nursing women or women intending to conceive during the course of the study or have a positive serum pregnancy test at Screening or a positive urine pregnancy test during the study.

• Women of childbearing potential (unless surgically sterilized by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years) not using a highly effective method of birth control.

• Non-surgically sterile males and males with partners of childbearing potential not willing to use a condom with spermicide for the duration of their participation in the study plus an additional 30 days following study drug administration and to ensure that their partner is using a highly effective method of birth control such as combined oral contraceptives, implants, injectables or an IUD.

• Respiratory tract infections or worsening of asthma or changes in asthma medications within 6 weeks before Screening/Baseline.

• Current cigarette smokers or former smokers with a smoking history of greater than 10 pack years or who stopped smoking within 12 months preceding enrolment in the study.

• Positive urine cotinine test at Screening.

• History of illicit drug use or alcohol abuse within 12 months before Screening.

• Positive test for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV) at Screening.

• Any medication that are known to prolong QT / QTc interval.

• Any of the following concomitant medications preceding the administration of salbutamol during Screening and preceding the administration of the study drug:

• Oral or i.v. corticosteroids within 1 month;

• Inhaled or intranasal corticosteroids within 48 hours;

• Long acting Beta-2-agonists within 24 hours;

• Short acting Beta-2-agonists within 8 hours;

• Anticholinergic aerosols within 24 hours; and

• Theophylline-containing products within 48 hours.

• Use of NSAIDs within 7 days preceding the administration of salbutamol during Screening and throughout the study.

• Use of antihistaminic drugs within 3 days preceding the administration of salbutamol during Screening.

• Use of an investigational product or participation in a clinical trial using an investigational product within 30 days before dosing or within 90 days in the case of long-acting products (ex.: Depo-medrol) or biologics with a long-acting half-life (ex.: monoclonal antibodies).